Production of the Auger emitter 119Sb for targeted radionuclide therapy using a small PET-cyclotron

Applied Radiation and Isotopes

Volumn 67, Issue 1, 2009, Pages 34-38

  Thisgaard, H ^a,b   Jensen, M ^a,b  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Auger electrons; Cancer; Excitation function; Nuclear reaction; Radiochemical separation; Radionuclide therapy; Sb 119

Indexed keywords

ATOMS; AUGERS; CYCLOTRONS; ISOTOPES; NUCLEAR REACTORS; TUMORS;

AUGER ELECTRONS; CANCER; EXCITATION FUNCTION; NUCLEAR REACTION; RADIOCHEMICAL SEPARATION; RADIONUCLIDE THERAPY; SB-119;

RADIOISOTOPES;

ANTIMONY; ANTIMONY 119; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; AUGER ELECTRON SPECTROSCOPY; CANCER RADIOTHERAPY; CANCER THERAPY; CYCLOTRON; DOSIMETRY; HALF LIFE TIME; IRRADIATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY; RADIOCHEMISTRY; TARGETED RADIOTHERAPY;

ANTIMONY; CYCLOTRONS; NEOPLASMS; RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 56349109015     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2008.09.003     Document Type: Article

References (28)

1. Adelstein S., Kassis A., Bodei L., and Mariani G. Radiotoxicity of iodine-125 and other Auger-electron-emitting radionuclides: background to therapy. Cancer Biother. Radiopharmaceut. 18 3 (2003) 301-316
2. Baluev A., Mityakhina V., Krasnikov L., Galkin B., and Besnosyuk V. Recovery of antimony-125 from tin-124 irradiated by neutrons. Czech. J. Phys. 53 (2003) A417-A423
3. Behr T., Behe M., Lohr M., Sgouros G., Angerstein C., Wehrmann E., Nebendahl K., and Becker W. Therapeutic advantages of Auger electron-over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur. J. Nucl. Med. 27 7 (2000) 753-765
4. Blann, M., 1991. ALICE/91 Computer Code.
5. Bohr A., and Mottelson B. Nuclear Structure vol. 1 (1998), World Scientific Publishing Co. Pte. Ltd., Singapore
6. Capello A., Krenning E., Breeman W., Bernard B., and de Jong M. Peptide receptor radionuclide therapy in vitro using [In-111-DTPA(0)]octreotide. J. Nucl. Med. 44 1 (2003) 98-104
7. Chen P., Wang J., Hope K., Jin L., Dick J., Camron R., Brandwein J., Minden M., and Reilly R. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with In-111 in human myeloid leukemia cells. J. Nucl. Med. 47 5 (2006) 827-836
8. Costantini D.L., Chan C., Cai Z., Vallis K.A., and Reilly R.M. 111In-labeled Trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J. Nucl. Med. 48 8 (2007) 1357-1368
9. Forrer F., Uusijarvi H., Storch D., Maecke H., and Mueller-Brand J. Treatment with Lu-177-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with Y-90-DOTATOC. J. Nucl. Med. 46 8 (2005) 1310-1316
10. Forrer F., Valkema R., Kwekkeboom D., de Jong M., and Krenning E. Peptide receptor radionuclide therapy. Best Pract. Res. Clin. Endocrinol. Metab. 21 1 (2007) 111-129
11. Howell R. Radiation spectra for Auger-electron emitting radionuclides-Report no. 2 of Aapm-Nuclear-Medicine-Task-Group no. 6. Med. Phys. 19 6 (1992) 1371-1383
12. Humm J., Howell R., and Rao D. Dosimetry of Auger-electron-emitting radionuclides-Report no. 3 of Aapm Nuclear-Medicine Task Group no. 6. Med. Phys. 21 12 (1994) 1901-1915
13. IAEA, 2007. Charged-particle cross section database for medical radioisotope production 〈http://www-nds.iaea.or.at/medical/〉.
14. Janson E., Westlin J., Ohrvall U., Oberg K., and Lukinius A. Nuclear localization of In-111 after intravenous injection of [In-111-DTPA-D-Phe(1)]-octreotide in patients with neuroendocrine tumors. J. Nucl. Med. 41 9 (2000) 1514-1518
15. Johnson C., and Kernell R. (p,n) Cross sections and strength functions for 3 MeV to 5.5 MeV protons on indium and on Sn isotopes. Phys. Rev. C 2 2 (1970) 639
16. Johnson C., Bair J., Jones C., Penny S., and Smith D. P-wave size resonances observed by (p,n) reaction for 2.6-MeV to 7-MeV protons incident on isotopes of Sn. Phys. Rev. C 15 1 (1977) 196-216
17. Kassis A., and Adelstein S. Radiobiologic principles in radionuclide therapy. J. Nucl. Med. 46 (2005) 4S-12S
18. Lovchikova G., Salnikov O., Simakov S., Trufanov A., Kotelnikova G., Pilz V., and Streil T. Study of the mechanism of the reactions Zr-94(p,n)Nb-94, Sn-119(p,n)Sb-119, and Sn-122(p,n)Sb-122 in the proton energy-range 6-9 MeV. Sov. J. Nucl. Phys.-USSR 31 1 (1980) 1-5
19. Michel R., Brechbiel M., and Mattes M. A comparison of 4 radionuclides conjugated to antibodies for single-cell kill. J. Nucl. Med. 44 4 (2003) 632-640
20. Musthafa M., Sharma M., Singh B., and Prasad R. Measurement and analysis of cross sections for (p,n) reactions in V-51 and In-113. Appl. Radiat. Isot. 62 3 (2005) 419-428
21. Nervik, W., 1960. The radiochemistry of tin. Subcommittee on Radiochemistry, National Academy of Sciences, National Research Council, Washington.
22. O'Donnell R. Nuclear localizing sequences: an innovative way to improve targeted radiotherapy. J. Nucl. Med. 47 5 (2006) 738-739
23. Q-value Calculator, 2007. National Nuclear Data Center. Brookhaven National Laboratory 〈http://www.nndc.bnl.gov/qcalc/〉.
24. Reilly R.M., Kiarash R., Cameron R.G., Porlier N., Sandhu J., Hill R.P., Vallis K., Hendler A., and Gariepy J. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J. Nucl. Med. 41 3 (2000) 429-438
25. 119Sb-a potent Auger emitter for targeted radionuclide therapy. Med. Phys. 35 9 (2008) 3839-3846
26. van Essen M., Krenning E., Bakker W., de Herder W., van Aken M., and Kwekkeboom D. Peptide receptor radionuclide therapy with Lu-177-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur. J. Nucl. Med. Mol. Imaging 34 8 (2007) 1219-1227
27. WWW Table of Radioactive Isotopes, 2004 〈http://ie.lbl.gov/toi/〉 (version 2.1).
28. Ziegler, J., Ziegler, M., Biersack, J., 2006. SRIM 2006 (2006.02).